{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:17:12Z","timestamp":1790972232107,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T00:00:00Z","timestamp":1340236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s15010-012-0273-2","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T05:20:05Z","timestamp":1340169605000},"page":"15-20","source":"Crossref","is-referenced-by-count":28,"title":["The efficacy of voriconazole in 24 ocular Fusarium infections"],"prefix":"10.1007","volume":"41","author":[{"given":"P.","family":"Troke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Obenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Gaujoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-L.","family":"Bienvenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Grenouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ranque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chaumeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Borderie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,21]]},"reference":[{"key":"273_CR1","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.ophtha.2006.05.035","volume":"113","author":"L Xie","year":"2006","unstructured":"Xie L, Zhong W, Shi W, Sun S. Spectrum of fungal keratitis in north China. Ophthalmology. 2006;113:1943\u20138.","journal-title":"Ophthalmology"},{"key":"273_CR2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jama.296.8.953","volume":"296","author":"DC Chang","year":"2006","unstructured":"Chang DC, Grant GB, O\u2019Donnell K, et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA. 2006;296:953\u201363.","journal-title":"JAMA"},{"key":"273_CR3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00014-07","volume":"20","author":"M Nucci","year":"2007","unstructured":"Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20:695\u2013704.","journal-title":"Clin Microbiol Rev"},{"key":"273_CR4","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/eye.2008.298","volume":"23","author":"SJ Tuft","year":"2009","unstructured":"Tuft SJ, Tullo AB. Fungal keratitis in the United Kingdom 2003\u20132005. Eye. 2009;23:1308\u201313.","journal-title":"Eye"},{"key":"273_CR5","first-page":"890","volume":"25","author":"N Rondeau","year":"2002","unstructured":"Rondeau N, Bourcier T, Chaumeil C, et al. Fungal keratitis at the Centre Hospitalier National d\u2019Ophtalmologie des Quinze-Vingts: retrospective study of 19 cases. J Fr Ophtalmol. 2002;25:890\u20136.","journal-title":"J Fr Ophtalmol"},{"key":"273_CR6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3109\/02713683.2010.506968","volume":"35","author":"S Senthilkumari","year":"2010","unstructured":"Senthilkumari S, Lalitha P, Prajna NV, et al. Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans. Curr Eye Res. 2010;35:953\u201360.","journal-title":"Curr Eye Res"},{"key":"273_CR7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ajo.2010.01.024","volume":"149","author":"YC Shen","year":"2010","unstructured":"Shen YC, Wang CY, Tsai HY, Lee HN. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. Am J Ophthalmol. 2010;149:916\u201321.","journal-title":"Am J Ophthalmol"},{"key":"273_CR8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1442-9071.2008.01911.x","volume":"37","author":"D Lau","year":"2009","unstructured":"Lau D, Leung L, Ferdinands M, et al. Penetration of 1\u00a0% voriconazole eye drops into human vitreous humour: a prospective, open-label study. Clin Exp Ophthalmol. 2009;37:197\u2013200.","journal-title":"Clin Exp Ophthalmol"},{"key":"273_CR9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archopht.122.1.42","volume":"122","author":"SM Hariprasad","year":"2004","unstructured":"Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122:42\u20137.","journal-title":"Arch Ophthalmol"},{"key":"273_CR10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/archophthalmol.2007.8","volume":"126","author":"GA Vemulakonda","year":"2008","unstructured":"Vemulakonda GA, Hariprasad SM, Mieler WF, Prince RA, Shah GK, Van Gelder RN. Aqueous and vitreous concentrations following topical administration of 1\u00a0% voriconazole in humans. Arch Ophthalmol. 2008;126:18\u201322.","journal-title":"Arch Ophthalmol"},{"key":"273_CR11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/bjo.2007.136515","volume":"92","author":"SM Hariprasad","year":"2008","unstructured":"Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol. 2008;92:871\u20138.","journal-title":"Br J Ophthalmol"},{"key":"273_CR12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/cid\/ciq204","volume":"52","author":"J Riddell 4th","year":"2011","unstructured":"Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis. 2011;52:648\u201353.","journal-title":"Clin Infect Dis"},{"key":"273_CR13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/archophthalmol.2010.102","volume":"128","author":"NV Prajna","year":"2010","unstructured":"Prajna NV, Mascarenhas J, Krishnan T, et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis. Arch Ophthalmol. 2010;128:672\u20138.","journal-title":"Arch Ophthalmol"},{"key":"273_CR14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1442-9071.2010.02473.x","volume":"39","author":"R Arora","year":"2011","unstructured":"Arora R, Gupta D, Goyal J, Kaur R. Voriconazole versus natamycin as primary treatment in fungal corneal ulcers. Clin Exp Ophthalmol. 2011;39:434\u201340.","journal-title":"Clin Exp Ophthalmol"},{"key":"273_CR15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/ICO.0b013e31818225f8","volume":"28","author":"EY Tu","year":"2009","unstructured":"Tu EY. Alternaria keratitis: clinical presentation and resolution with topical fluconazole or intrastromal voriconazole and topical caspofungin. Cornea. 2009;28:116\u20139.","journal-title":"Cornea"},{"key":"273_CR16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ajo.2006.07.033","volume":"143","author":"VY Bunya","year":"2007","unstructured":"Bunya VY, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol. 2007;143:151\u20133.","journal-title":"Am J Ophthalmol"},{"key":"273_CR17","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1086\/430062","volume":"40","author":"RR Klont","year":"2005","unstructured":"Klont RR, Eggink CA, Rijs AJ, Wesseling P, Verweij PE. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis. 2005;40:e110\u20132.","journal-title":"Clin Infect Dis"},{"key":"273_CR18","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3109\/02713680903254822","volume":"34","author":"M Cakir","year":"2009","unstructured":"Cakir M, Imamo\u011flu S, Ceki\u00e7 O, et al. An outbreak of early-onset endophthalmitis caused by Fusarium species following cataract surgery. Curr Eye Res. 2009;34:988\u201395.","journal-title":"Curr Eye Res"},{"key":"273_CR19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ajo.2005.03.030","volume":"140","author":"ML Durand","year":"2005","unstructured":"Durand ML, Kim IK, D\u2019Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol. 2005;140:552\u20134.","journal-title":"Am J Ophthalmol"},{"key":"273_CR20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/bjo.84.8.928d","volume":"84","author":"A Reis","year":"2000","unstructured":"Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol. 2000;84:932\u20133.","journal-title":"Br J Ophthalmol"},{"key":"273_CR21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ajo.2009.08.004","volume":"149","author":"S Bang","year":"2010","unstructured":"Bang S, Edell E, Eghrari AO, Gottsch JD. Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis. Am J Ophthalmol. 2010;149:66\u20139.","journal-title":"Am J Ophthalmol"},{"key":"273_CR22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1550-7408.2005.00082.x","volume":"53","author":"FL Schuster","year":"2006","unstructured":"Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol. 2006;53:121\u20136.","journal-title":"J Eukaryot Microbiol"},{"key":"273_CR23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/ICO.0b013e3181cbfa2c","volume":"29","author":"EY Tu","year":"2010","unstructured":"Tu EY, Joslin CE, Shoff ME. Successful treatment of chronic stromal Acanthamoeba keratitis with oral voriconazole monotherapy. Cornea. 2010;29:1066\u20138.","journal-title":"Cornea"},{"key":"273_CR24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","volume":"46","author":"K Tan","year":"2006","unstructured":"Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46:235\u201343.","journal-title":"J Clin Pharmacol"},{"key":"273_CR25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/jop.2010.0046","volume":"26","author":"H Kadikoy","year":"2010","unstructured":"Kadikoy H, Barkmeier A, Peck B, Carvounis PE. Persistent photopsia following course of oral voriconazole. J Ocul Pharmacol Ther. 2010;26:387\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"273_CR26","first-page":"391","volume":"4","author":"D Al-Badriyeh","year":"2010","unstructured":"Al-Badriyeh D, Neoh CF, Stewart K, Kong DC. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis. Clin Ophthalmol. 2010;4:391\u2013405.","journal-title":"Clin Ophthalmol"},{"key":"273_CR27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/ICO.0b013e31817780d5","volume":"27","author":"JD Bullock","year":"2008","unstructured":"Bullock JD. An outbreak of Fusarium keratitis associated with contact lens use in the northeastern United States. Cornea. 2008;27:973\u20134.","journal-title":"Cornea"},{"key":"273_CR28","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1111\/j.1755-3768.2010.01946.x","volume":"89","author":"T Gaujoux","year":"2011","unstructured":"Gaujoux T, Borsali E, Goldschmidt P, et al. Fungal keratitis in France. Acta Ophthalmol. 2011;89:e215\u20136.","journal-title":"Acta Ophthalmol"},{"key":"273_CR29","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/ICO.0b013e31813e32a6","volume":"26","author":"SK Rao","year":"2007","unstructured":"Rao SK, Lam PT, Li EY, Yuen HK, Lam DS. A case series of contact lens-associated Fusarium keratitis in Hong Kong. Cornea. 2007;26:1205\u20139.","journal-title":"Cornea"},{"key":"273_CR30","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","volume":"36","author":"JR Perfect","year":"2003","unstructured":"Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122\u201331.","journal-title":"Clin Infect Dis"},{"key":"273_CR31","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1128\/AAC.00286-10","volume":"54","author":"O Lortholary","year":"2010","unstructured":"Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54:4446\u201350.","journal-title":"Antimicrob Agents Chemother"},{"key":"273_CR32","first-page":"1165","volume":"3","author":"M Stanzani","year":"2007","unstructured":"Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: focus on voriconazole. Ther Clin Risk Manag. 2007;3:1165\u201373.","journal-title":"Ther Clin Risk Manag"},{"key":"273_CR33","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1128\/AAC.01126-08","volume":"53","author":"A Dupuis","year":"2009","unstructured":"Dupuis A, Tournier N, Le Moal G, Venisse N. Preparation and stability of voriconazole eye drop solution. Antimicrob Agents Chemother. 2009;53:798\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"273_CR34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajo.2004.08.077","volume":"139","author":"SM Breit","year":"2005","unstructured":"Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol. 2005;139:135\u201340.","journal-title":"Am J Ophthalmol"},{"key":"273_CR35","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/cid\/cir355","volume":"53","author":"AML Oude Lashof","year":"2011","unstructured":"Oude Lashof AML, Rothova A, Sobel JD, et al. Ocular manifestations of candidemia. Clin Infect Dis. 2011;53:262\u20138.","journal-title":"Clin Infect Dis"},{"key":"273_CR36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tox.2009.01.008","volume":"258","author":"M Kernt","year":"2009","unstructured":"Kernt M, Kampik A. Intracameral voriconazole: in vitro safety for human ocular cells. Toxicology. 2009;258:84\u201393.","journal-title":"Toxicology"},{"key":"273_CR37","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/IAE.0b013e31818d4b9b","volume":"29","author":"M Kernt","year":"2009","unstructured":"Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina. 2009;29:362\u201370.","journal-title":"Retina"},{"key":"273_CR38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archophthalmol.2007.71","volume":"126","author":"D Lau","year":"2008","unstructured":"Lau D, Fedinands M, Leung L, et al. Penetration of voriconazole, 1\u00a0%, eyedrops into human aqueous humor: a prospective open-label study. Arch Ophthalmol. 2008;126:343\u20136.","journal-title":"Arch Ophthalmol"},{"key":"273_CR39","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/ICO.0b013e318142bff3","volume":"26","author":"DJ Galarreta","year":"2007","unstructured":"Galarreta DJ, Tuft SJ, Ramsay A, Dart JK. Fungal keratitis in London: microbiological and clinical evaluation. Cornea. 2007;26:1082\u20136.","journal-title":"Cornea"},{"key":"273_CR40","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jac\/dkm518","volume":"61","author":"A Espinel-Ingroff","year":"2008","unstructured":"Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother. 2008;61:616\u201320.","journal-title":"J Antimicrob Chemother"},{"key":"273_CR41","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/jac\/dkp095","volume":"63","author":"M Azor","year":"2009","unstructured":"Azor M, Cano J, Gen\u00e9 J, Guarro J. High genetic diversity and poor in vitro response to antifungals of clinical strains of Fusarium oxysporum. J Antimicrob Chemother. 2009;63:1152\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"273_CR42","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1128\/AAC.01618-06","volume":"51","author":"M Azor","year":"2007","unstructured":"Azor M, Gen\u00e9 J, Cano J, Guarro J. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother. 2007;51:1500\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"273_CR43","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","volume":"46","author":"MA Pfaller","year":"2002","unstructured":"Pfaller MA, Messer SA, Hollis RJ, Jones RN; SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46:1032\u20137.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-012-0273-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-012-0273-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-012-0273-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T13:38:00Z","timestamp":1559482680000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-012-0273-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,21]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["273"],"URL":"https:\/\/doi.org\/10.1007\/s15010-012-0273-2","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,21]]}}}